The National Institute for Health and Care Excellence (NICE) has recommended the immunotherapy combination of ipilimumab plus nivolumab for patients with previously untreated advanced renal cell carcinoma (RCC) for use within NHS England.

Additional data collected since 2019 through the Cancer Drugs Fund and from the Checkmate-214 trial was used in the submission. The data showed improved overall survival and response of the cancer to treatment compared to sunitinib.  The combination will continue to be a treatment option for patients diagnosed with intermediate- or poor-risk advanced RCC in England.

Read more in The Pharma Letter here